Antipsychotics in Wolff-Parkinson-White Syndrome
Wolff-Parkinson-White Syndrome (WPW) is a rare ventricular pre-excitation syndrome due to the presence of an atrioventricular accessory pathway. WPW patients are prone to fatal arrhythmias. Antipsychotics are FDA-approved for various psychiatric illnesses which increases the possibility of patients with WPW receiving such medications. Currently, there is scarce evidence on the safety of antipsychotics in WPW patients.
Source: Biological Psychiatry - Category: Psychiatry Authors: Hassaan Gomaa, Sean Nutting, Andrew Francis, Charles Mormando, Alfredo Bellon Tags: Research Method: Pharmacology Source Type: research
More News: Arrhythmia | Drugs & Pharmacology | Parkinson's Disease | Psychiatry | Wolff-Parkinson-White Syndrome